Clinic TB-500

READING · REFERENCES

Twenty-six peer-reviewed sources, sortable and searchable.

Every claim on this site attaches to a citation below. Sort by year, filter by species, or search by author. All identifiers link to PubMed, PMC, or the publishing journal.

Back to the researchRead the FAQ

Citation console

The table below renders the full reference set. Sort by year for chronological reading from Cassimeris 1992 to Yu 2025. Filter by species to separate human Phase I/II/III work from rodent, porcine, and equine preclinical studies. Search by author for the named lineages (Sosne and Kleinman on corneal repair; Bock-Marquette, Smart, and Riley on cardiac repair; Morris and Chopp on stroke; Ruff and Wang on human Phase I safety).

Identifiers are rendered in monospace: DOIs in the format 10.xxxx/..., NCT identifiers in the format NCT02600429, CAS in the format 885340-08-9. Where a PMC or PubMed URL is available, the citation row is linked directly to the open-access record.

Citation key

Cyan rows indicate human clinical-trial sources — Phase I safety in healthy volunteers, Phase II/III ophthalmic and cardiac programmes, and the published clinical-biomarker record. Lime rows indicate preclinical and in-vitro sources — rodent and porcine models, equine pharmacokinetics, and biochemical structural work. Orange rows indicate regulatory and review sources — the modern Tβ4 reviews and the disambiguation literature.

The categorical legend matches the site colour vocabulary. No reference is categorised by colour alone — the journal, year, and species columns in the console table carry the same information independently.

  1. Cassimeris L, Safer D, Nachmias VT, Zigmond SH. Interaction of thymosin beta 4 with muscle and platelet actin: implications for actin sequestration in resting platelets. Biochemistry. 1992;31(35):8290-8298. ↗
  2. Irobi E, Aguda AH, Larsson M, Guerin C, Yin HL, Burtnick LD, Blanchoin L, Robinson RC. Structural basis of actin sequestration by thymosin-β4: implications for WH2 proteins. EMBO Journal. 2004;23(18):3599-3608. ↗
  3. Malinda KM, Sidhu GS, Mani H, Banaudha K, Maheshwari RK, Goldstein AL, Kleinman HK. Thymosin β4 accelerates wound healing. Journal of Investigative Dermatology. 1999;113(3):364-368. ↗
  4. Sosne G, Szliter EA, Barrett R, Kernacki KA, Kleinman H, Hazlett LD. Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury. Experimental Eye Research. 2002;74(2):293-299. ↗
  5. Philp D, Badamchian M, Scheremeta B, Nguyen M, Goldstein AL, Kleinman HK. Thymosin β4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair and Regeneration. 2003;11(1):19-24. ↗
  6. Bock-Marquette I, Saxena A, White MD, DiMaio JM, Srivastava D. Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. ↗
  7. Smart N, Risebro CA, Melville AAD, Moses K, Schwartz RJ, Chien KR, Riley PR. Thymosin β4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445(7124):177-182. ↗
  8. Morris DC, Chopp M, Zhang L, Lu M, Zhang ZG. Thymosin β4 improves functional neurological outcome in a rat model of embolic stroke. Neuroscience. 2010;169(2):674-682. ↗
  9. Morris DC, Cui Y, Cheung WL, Lu M, Zhang L, Zhang ZG, Chopp M. A dose-response study of thymosin β4 for the treatment of acute stroke. Journal of the Neurological Sciences. 2014;345(1-2):61-67. ↗
  10. Qiu P, Wheater MK, Qiu Y, Sosne G. Thymosin β4 inhibits TNF-α-induced NF-κB activation, IL-8 expression, and the sensitizing effects of its partners PINCH-1 and ILK. FASEB Journal. 2011;25(6):1815-1826. ↗
  11. Philp D, Nguyen M, Scheremeta B, St-Surin S, Villa AM, Orgel A, Kleinman HK, Elkin M. Thymosin β4 increases hair growth by activation of hair follicle stem cells. FASEB Journal. 2004;18(2):385-387. ↗
  12. Tokura Y, Nakayama Y, Fukada S, Nara N, Yamamoto H, Matsuda R, Hara T. Muscle injury-induced thymosin β4 acts as a chemoattractant for myoblasts. Journal of Biochemistry. 2011;149(1):43-48. ↗
  13. Ruff D, Crockford D, Girardi G, Zhang Y. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Annals of the New York Academy of Sciences. 2010;1194:223-229. ↗
  14. Wang X, Liu L, Qi L, Lei C, Li P, Wang Y, Liu C, Bai H, Han C, Sun Y, Liu J. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers. Journal of Cellular and Molecular Medicine. 2021;25(16):7841-7852. ↗
  15. Sosne G, Kleinman HK, Springs C, Gross RH, Sung J, Kang S. 0.1% RGN-259 (Thymosin β4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial. International Journal of Molecular Sciences. 2022;24(1):554. ↗
  16. Esposito S, Deventer K, Goeyens L, Van Eenoo P. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography–mass spectrometry. Analytica Chimica Acta. 2012;752:99-104. ↗
  17. Wei C, Kumar S, Kim IK, Gupta S. Systemic dosing of thymosin beta 4 before and after ischemia does not attenuate global myocardial ischemia-reperfusion injury in pigs. Frontiers in Pharmacology. 2016;7:115. ↗
  18. Romanic AM, Krais T, Lehmann K, et al. Thymosin β4 and its cleavage product Ac-SDKP are down-regulated in left ventricular myocardium of patients with advanced heart failure. Journal of Heart and Lung Transplantation. 2015;34(10):S138. ↗
  19. Lee S, Lee H, Bae S, Kim E, Oh GT, Park H, Yeon JE, Byun KS, Kim K. Targeted deletion of thymosin beta 4 in hepatic stellate cells ameliorates liver fibrosis in a transgenic mouse model. Cells. 2023;12(12):1658. ↗
  20. Yu H, Wang B, Li Z, et al. Tβ4-exosome-loaded hemostatic and antibacterial hydrogel to improve vascular regeneration and modulate macrophage polarization for diabetic wound treatment. Materials Today Bio. 2025;30:101585. ↗
  21. Yang J, Sosne G, Kleinman HK, Springs C, Bhamidipati A, et al. Engineered Tandem Thymosin Peptide Promotes Corneal Wound Healing. International Journal of Molecular Sciences. 2024;25(19):10347. ↗
  22. Sosne G, Kleinman HK, Springs C. (Companion narrative review of the RGN-259 ARISE / SEER ophthalmic Phase II/III programmes for dry eye and neurotrophic keratopathy.) ↗
  23. Xu T, Tao S, Yu D, Wang J, Wang G, Wang M, Yao Z. Thymosin β4 enhances the healing of medial collateral ligament injury in rat. Regulatory Peptides. 2013;184:1-5. ↗
  24. Xing Y, Ye Y, Zuo H, Li Y. Progress on the function and application of thymosin β4. Frontiers in Endocrinology. 2021;12:767785. ↗
  25. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opinion on Biological Therapy. 2012;12(1):37-51. ↗
  26. U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee Meeting Materials — TB-500 (Thymosin Beta-4 fragment, free base and acetate) Section 503A Bulks List nomination. Docket FDA-2025-N-6895. Scheduled review 23 July 2026. ↗
  27. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. ↗
  28. Cha HJ, Jeong MJ, Kleinman HK. Role of thymosin beta4 in tumor metastasis and angiogenesis. J Natl Cancer Inst. 2003;95(22):1674-1680. ↗
  29. Wang WS, et al. Thymosin beta 4 is overexpressed in human pancreatic cancer cells and stimulates proinflammatory cytokine secretion and JNK activation. Cancer Biol Ther. 2008;7(3):422-427. ↗
  30. Cooper TM, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012;1268:102-111. ↗
  31. Spurney CF, et al. Evaluation of skeletal and cardiac muscle function after chronic administration of thymosin beta-4 in the dystrophin deficient mouse. PLoS One. 2010;5(2):e8976. ↗
  32. Thomas A, et al. TB500/TB1000 and SGF1000: A scientific approach for a better understanding of doping-relevant peptide preparations. Drug Test Anal. 2023;15(4):427-438. ↗